322 related articles for article (PubMed ID: 31971453)
1. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A.
Cook K; Forbes SP; Adamski K; Ma JJ; Chawla A; Garrison LP
J Med Econ; 2020 May; 23(5):501-512. PubMed ID: 31971453
[No Abstract] [Full Text] [Related]
2. Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.
Oldenburg J; Chambost H; Liu H; Hawes C; You X; Yang X; Newman V; Robinson TM; Hatswell AJ; Hinds D; Santos S; Ozelo M
Adv Ther; 2024 Jun; 41(6):2267-2281. PubMed ID: 38616241
[TBL] [Abstract][Full Text] [Related]
3. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
Astermark J; Buckner TW; Frenzel L; Hatswell AJ; You X; Liu H; Goodman E; Santos S; Hawes C; Hinds D; Klamroth R
Haemophilia; 2023 Jul; 29(4):1087-1094. PubMed ID: 37347645
[TBL] [Abstract][Full Text] [Related]
4. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
Ozelo MC; Mahlangu J; Pasi KJ; Giermasz A; Leavitt AD; Laffan M; Symington E; Quon DV; Wang JD; Peerlinck K; Pipe SW; Madan B; Key NS; Pierce GF; O'Mahony B; Kaczmarek R; Henshaw J; Lawal A; Jayaram K; Huang M; Yang X; Wong WY; Kim B;
N Engl J Med; 2022 Mar; 386(11):1013-1025. PubMed ID: 35294811
[TBL] [Abstract][Full Text] [Related]
5. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
Mahlangu J; Kaczmarek R; von Drygalski A; Shapiro S; Chou SC; Ozelo MC; Kenet G; Peyvandi F; Wang M; Madan B; Key NS; Laffan M; Dunn AL; Mason J; Quon DV; Symington E; Leavitt AD; Oldenburg J; Chambost H; Reding MT; Jayaram K; Yu H; Mahajan R; Chavele KM; Reddy DB; Henshaw J; Robinson TM; Wong WY; Pipe SW;
N Engl J Med; 2023 Feb; 388(8):694-705. PubMed ID: 36812433
[TBL] [Abstract][Full Text] [Related]
6. Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations.
Garrison LP; Pezalla E; Towse A; Yang H; Faust E; Wu EQ; Li N; Sawyer EK; Recht M
Value Health; 2021 Nov; 24(11):1628-1633. PubMed ID: 34711363
[TBL] [Abstract][Full Text] [Related]
7. Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid.
Zemplenyi A; Leonard J; DiStefano MJ; Anderson KE; Wright GC; Mendola ND; Nair K; McQueen RB
Pharmacoeconomics; 2024 Mar; 42(3):319-328. PubMed ID: 37989969
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
[TBL] [Abstract][Full Text] [Related]
9. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.
Pasi KJ; Laffan M; Rangarajan S; Robinson TM; Mitchell N; Lester W; Symington E; Madan B; Yang X; Kim B; Pierce GF; Wong WY
Haemophilia; 2021 Nov; 27(6):947-956. PubMed ID: 34378280
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1.
O'Mahony B; Dunn AL; Leavitt AD; Peyvandi F; Ozelo MC; Mahlangu J; Peerlinck K; Wang JD; Lowe GC; Tan CW; Giermasz A; Tran H; Khoo TL; Cockrell E; Pepperell D; Chambost H; López Fernández MF; Kazmi R; Majerus E; Skinner MW; Klamroth R; Quinn J; Yu H; Wong WY; Robinson TM; Pipe SW
J Thromb Haemost; 2023 Dec; 21(12):3450-3462. PubMed ID: 37678546
[TBL] [Abstract][Full Text] [Related]
11. Valoctocogene Roxaparvovec: First Approval.
Blair HA
Drugs; 2022 Sep; 82(14):1505-1510. PubMed ID: 36214970
[TBL] [Abstract][Full Text] [Related]
12. Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B.
Dougherty JA; Dougherty KM
Ann Pharmacother; 2023 Nov; ():10600280231202247. PubMed ID: 37978816
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment.
Symington E; Rangarajan S; Lester W; Madan B; Pierce GF; Raheja P; Robinson TM; Osmond D; Russell CB; Vettermann C; Agarwal SK; Li M; Wong WY; Laffan M
Haemophilia; 2024 Mar; 30(2):320-330. PubMed ID: 38317480
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
[TBL] [Abstract][Full Text] [Related]
15. Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia.
Thornburg CD; Simmons DH; von Drygalski A
BioDrugs; 2023 Sep; 37(5):595-606. PubMed ID: 37490225
[TBL] [Abstract][Full Text] [Related]
16. Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States.
Yan S; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Wilson M
J Med Econ; 2024; 27(1):758-765. PubMed ID: 38708771
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy in hemophilia A: a cost-effectiveness analysis.
Machin N; Ragni MV; Smith KJ
Blood Adv; 2018 Jul; 2(14):1792-1798. PubMed ID: 30042145
[TBL] [Abstract][Full Text] [Related]
18. The Arrival of Gene Therapy for Patients with Hemophilia A.
Castaman G; Di Minno G; De Cristofaro R; Peyvandi F
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142153
[TBL] [Abstract][Full Text] [Related]
19. Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
Long BR; Veron P; Kuranda K; Hardet R; Mitchell N; Hayes GM; Wong WY; Lau K; Li M; Hock MB; Zoog SJ; Vettermann C; Mingozzi F; Schweighardt B
Mol Ther; 2021 Feb; 29(2):597-610. PubMed ID: 33309883
[TBL] [Abstract][Full Text] [Related]
20. Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A.
Agarwal S; Hermans C; Miesbach W; Peyvandi F; Sidonio R; Osmond D; Newman V; Henshaw J; Pipe S
Haemophilia; 2024 Apr; ():. PubMed ID: 38684460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
